Floatz Rating
CC47/100
Confidence
Indicative
Sponsor
New York Medical College
Modality
Cell therapy
Development Phase
Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
32Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01586455CT.gov Human Placental-Derived Stem Cell Transplantation | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Fucosidosis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Human Placental Derived Stem Cell (this asset) | New York Medical College | P1 | CC · 47 |
| Busulfanum | Masonic Cancer Center, University of Minnesota | P2/3 | BB |
| Cyclophosphamide | Masonic Cancer Center, University of Minnesota | P2/3 | BB |
| Cyclosporin A | Masonic Cancer Center, University of Minnesota | P2 | BB |
| Anti-Human T-Lymphocyte Immunoglobulin, Rabbit | Masonic Cancer Center, University of Minnesota | P2/3 | B |
| Cald Hr-D | Masonic Cancer Center, University of Minnesota | P2 | CCC |
| Campath-1H | Masonic Cancer Center, University of Minnesota | P2 | CCC |
Other indications for Human Placental Derived Stem Cell
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Mucopolysaccharidosis Type 6 | — | P1 | CC · 47 |
| Adrenoleukodystrophy | — | P1 | CC · 47 |
| Mucopolysaccharidosis Type 1 | — | P1 | CC · 47 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- BusulfanumMasonic Cancer Center, University of MinnesotaBB
- CyclophosphamideMasonic Cancer Center, University of MinnesotaBB
- Cyclosporin AMasonic Cancer Center, University of MinnesotaBB
- Anti-Human T-Lymphocyte Immunoglobulin, RabbitMasonic Cancer Center, University of MinnesotaB
- Cald Hr-DMasonic Cancer Center, University of MinnesotaCCC
Citation
Floatz Terminal. Human Placental Derived Stem Cell in Fucosidosis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/human-placental-derived-stem-cell-fucosidosis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →